HealthDay News — Patients with fibromyalgia syndrome have high prevalence of anti-thyroid-stimulating hormone (TSH) receptor antibody (TRAb), according to a study published the International Journal of Rheumatic Diseases.

Kenya Nishioka, MD, PhD, from the Juntendo University Graduate School of Medicine in Tokyo, and colleagues tested for titers of free triiodothyronine, free thyroxine, TSH, antithyroid peroxidase antibody (TPOAb), antithyroglobulin antibody (TgAb), and TRAb in 207 patients with fibromyalgia syndrome. Twenty-five patients with subclinical hyper- or hypothyroidism, or overt hypothyroidism were excluded.

The researchers identified 69 patients with autoimmune thyroid diseases (37.9%). The prevalence of positivity for TRAb was 20.3%, TgAb was 16.5%, and TPOAb was 13.2%. The prevalence of TRAb positivity was high compared with control populations in previous studies, and TRAb titers were low. Compared with previous studies reporting on patients with fibromyalgia syndrome, the prevalence of TPOAb and TgAb positivity were not significantly higher. Identical clinical symptom profiles were seen for fibromyalgia syndrome patients with and without autoimmune thyroid disease.

“We found a high prevalence of autoimmune thyroid disease among 207 patients with clinically defined fibromyalgia syndrome, with TRAb being especially prominent among these patients,” the researchers wrote. “Further study is needed to evaluate changes in thyroid function among fibromyalgia syndrome patients with autoimmune thyroid disease.”


  1. Nishioka K, Uchida T, Usui C, et al. High prevalence of anti-TSH receptor antibody in fibromyalgia syndrome. In J Rheum Dis. 2016 Nov 30. doi:10.1111/1756-185X.12964 [Epub ahead of print].